A phase II trial of pertuzumab and trastuzumab in combination with capecitabine in patients with metastatic breast cancer who received prior trastuzumab combination chemotherapy.
Phase of Trial: Phase II
Latest Information Update: 19 May 2016
Price : $35 *
At a glance
- Drugs Capecitabine (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 16 May 2016 Status changed from recruiting to discontinued.
- 11 Nov 2013 New trial record